Eli Lilly and : Lilly Diabetes & Obesity ADA Update Presentation
June 07, 2022 at 09:12 am EDT
Share
Lilly Diabetes & Obesity
ADA Update
June 7, 2022
SAFE HARBOR PROVISION
This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform.
For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent filings with the Securities and Exchange Commission.
The company undertakes no duty to update forward-looking statements
except as required by applicable law
Not for promotional use
2022 LILLY ADA UPDATE
2
Introduction
Mike Mason, President, Lilly Diabetes
Tirzepatide SURMOUNT-1 Phase 3 Results & New Insights
Jeff Emmick, M.D., Ph.D., Vice President, Lilly Diabetes
Agenda
Product Development
Early Phase ADA Highlights & Portfolio Overview
Ruth Gimeno, Ph.D., Vice President, Lilly Diabetes and
Metabolic Research
Q&A
MOUNJAROTM NOW APPROVED IN THE U.S. FOR T2D
FIRST AND ONLY GIP AND GLP-1 RECEPTOR AGONIST AVAILABLE FOR PATIENTS
Delivered superior A1C reductions versus all comparators in Phase 3 SURPASS clinical trials
Although not indicated for weight loss, led to significantly greater weight reductions versus comparators in a key secondary endpoint
Shipments to wholesalers are underway and pharmacies will begin to see supply as prescriptions are written
Enabling new patient starts through patient support programs as we work to build broad access:
1 month sample (4 weeks) of starting 2.5 mg pens prior to HCP writing a 5 mg prescription
Copay program with out-of-pocket costs as little as $25 per month for eligible commercially insured patients
T2D=type 2 diabetes; HCP=healthcare professional
Not for promotional use
2022 LILLY ADA UPDATE
4
INNOVATION DRIVES EXPANDED STRATEGIC FOCUS
DIABETES AND OBESITY
OUR FOUNDATION
People
with
Diabetes
+
Improving and simplifying
glycemic control
OUR EXPANDED FOCUS
Obesity Diabetes
+
Disrupting disease progression in
Diabetes & Obesity to improve outcomes
Not for promotional use
2022 LILLY ADA UPDATE
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Eli Lilly and Company published this content on 07 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2022 13:11:07 UTC.
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
ELI LILLY AND COMPANY 
